Accumulation of nuclear p53 protein and prognosis of astrocytomas in childhood and adolescence

Clinical Neuropathology

Volumn 15, Issue 2, 1996, Pages 67-73

  Drach, L M ^a,b   Kammermeier, M ^a   Neirich, U ^a   Jacobi, G ^a   Kornhuber, B ^a   Lorenz, R ^a   Schlote, W ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Neurologisches Institut   (Germany)

Author keywords

Astrocytoma in childhood; Immunohistochemistry; p53; Survival

Indexed keywords

PROTEIN P53;

ADOLESCENT; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CHILD; CLINICAL ARTICLE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; PRIORITY JOURNAL; SURVIVAL;

ADOLESCENT; ASTROCYTOMA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029920688     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Ackermann H 1992 Biometrische Analyse von Stichproben, Version 3.07. Epsilon, Hochheim
2. Alfred DC, Clark GM, Elledge R Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL 1993 Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85: 845-855
3. Arai N, Nomura D, Yokola K, Wolf D, Brill E, Shohar O, Rotter V 1986 Immunologically distinct p53 molecules generated by alternative splicing. Mol Cell Biol 6: 3232-3239
4. Banks L, Matlashewski G, Crawford L 1986 Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159: 529-534
5. Bartek J, Bartkova J, Vojesek B, Staskova Z, Lukas J, Rejther A, Kovarik J, Midgley CA, Gannon JV, Lane DP 1991 Aberrant expression of the p53 onkoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6: 1699-1703
6. Chung R, Whaley J, Kley N, Anderson K, Louis D, Menon A, Hettlich C, Freiman R, Hedley-White ET, Martuza R, Jenkins R, Yandell D, Seizinger BR 1991 Tp53 gene mutations and 17p deletions in human astrocytomas. Genes Chrom Cancer 3: 323-331
7. Deimling A von, Eibl RH, Ohgaki H, Louis DN, von Amman K, Petersen I, Klethues P, Chung RY, Wiestler OD, Seizinger BR 1992 p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 52: 2987-2990
8. Di Sapio A, Mauro A, Cavalla P, Zappador C, Schiffer D 1994 Analysis of p53 gene mutation and EGRF gene amplification in 30 astrocytic tumors of childhood. Clin Neuropathol 13: 149
9. El-Azouzi M, Chung R Y, Farmer GE, Martuza RL, Black PM, Rouleau GA, Hettlich C, Hedley-White ET, Zenvas NT, Panagopoulos K, Nakamura Y, Gusella JF, Seiziger BR 1989 Loss of distinct regions on the short arm of chromosome 17 associated with tumorigenesis of human astrocytomas. Proc Natl Acad Sci USA 86: 7186-7190
10. Esrig D, Elmajian D, Grosheim S, Freeman JA, Stein JP, Chen S-C, Nichols PW, Skinner DG, Jones PA, Cote RJ 1994 Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331: 1259-1264
11. Frankel RH, Bayona W, Koslow M, Newcomb EW 1992 p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency. Cancer Res 52: 1427-1433
12. Fults D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM 1992 p53 mutations and loss of heterozygosity on chromosome 17 and 10 during human astrocytoma progression. Cancer Res 52: 674-679
13. Fults D, Pedone CA, Thomas GA, White R 1990 Allotype of human malignant astrocytoma. Cancer Res 50: 5784-5789
14. Gannon JV, Greaves R, Iggo R, Lane DP 1990 Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9: 1595-1602
15. Harlow E, Crawford LV, Pim DC, Williamson NM 1981 Monoclonal antibodies specific for simian virus 40 tumour antigenes. J Virol 39:861-869
16. Harris CC, Hollstein M 1993 Clinical implications of the p53 tumour supressor gene. N Engl J Med 318: 1318-1327
17. Holstein M, Sidransky D, Vogelstein B, Harris CC 1991 p53 mutations in human cancers. Science 253: 49-53
18. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukotomi T, Mukai K, Hirohashi S 1991 Nuclear p53 immunere action associated with poor prognosis of breast cancer. Jpn J Cancer Res 82: 835-840
19. James CD, Carlbom E, Dumanski JP, Hansen M, Nordenskjold M, Collins WP, Cavenee WW 1988 Clonal genomic alterations in glioma malignant stages. Cancer Res 48: 5546-5551
20. Kaplan EL, Meier P 1958 Nonparametric estimation from incomplete observations. JASA 53. 457-481
21. Karamitopoulou E, Perentes F, Diamantis I 1993 p53 protein expression in central nervous system tumours: An immunohistochemical study with CM 1 polyvalent and DO 7 monoclonal antibodies. Acta Neuropathol 85 611-616
22. Kern SE, Fearon ER, Tersmette KW, Enter line JP, Leppert M, Nakamura Y, White R, Vogelstein B, Hamilton SR 1989 Clinical and pathological associations with allelic loss in cotorectal carcinoma. JAMA 261, 3099-3103
23. Kleihues P, Burger PC, Scheithauer BW 1993 The new WHO classification of brain tumours. Brain Pathol 3: 255-268
24. Koga H, Zhang S, Kumanishi T, Washiyama K, Ichikawa T, Tanaka R, Mukawa J 1994 Analysis of p53 gene mutation in low- and high-grade astrocytomas by PCR-assisted single-strand conformation polymorphism and immunohistochemistry. Acta Neuropathol 87: 225-232
25. Kraus JA, Bolln C, Wolf HK, Schlegel U 1993 p53 alterations and clinical outcome in low grade astrocytomas. Clin Neuropathol 12: 254
26. Lane DP 1992 Cancer: p53, guardian of the genome. Nature 358: 15-16
27. Lane DP, Crawford LV 1979 T antigene is bound to a host protein in SV40-transformed cells. Nature 278: 261-263
28. Laureni-Puig P, Olschwang S, Delattre O, Remvikos Y, Asselan B, Melot T, Validire P, Muleris M, Girodet J, Salmon RJ 1992 Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 102: 1136-1141
29. Mantel N, Haenszel W 1959 Statistical aspects of the analysis of data from retrospective studies on disease. J Natl Cancer Inst 22 719-748
30. Marchetti A, Buttitta F, Merlo G, Diella F, Pellegrini S, Pepe S, Macchiarini P, Chella A, Angeletti CA, Callahan R 1993 p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 53: 2846-2851
31. Mashiyama S, Murakami Y, Yoshimoto T, Sekiya T, Hayashi K 1991 Detection of p53 gene mutations in human brain tumors by single-stranded conformation polymorphism analysis of polymerase chain reaction products. Oncogene 6: 1313-1318
32. Midgley CA, Fisher CJ, Baitek J, Vojtesek B, Lane D, Barnes DM 1992 Analysis of p53 expression in human tumors: An antibody raised against human p53 expressed in Escherichia coli. J Celt Sci 101 183-189
33. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B 1989 Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708
34. Oliner JD, Kinder KW, Melizer PS, Georges DL, Vogelstein B 1992 Amplification of a gene encoding a p53 associated protein in human sarcomas. Nature 358: 80-83
35. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B 1993 Oncoprotein MDM2 conceals the activation domain of tumor supressor p53. Nature 362: 857-860
36. Olumi AF, Tsai YC, Nithols PW, Skinner DG, Cain DR, Bender LI, Jones PA 1990 Allelic loss of chromosome 17p distinguishes high grade from low grade transitional carcinomas of the bladder. Cancer Res 50. 7081-7083
37. Pan S, Gries H, Bolik E, Giraldo M, Cervos-Navarro J, Brockmöller J, Roots I 1994 Comparative analysis of p53 gene and protein alterations on paraffin sections of human gliomas. Clin Neuropathol 13: 262
38. Quilan DC, Davidson AG, Sommers CL, Warden HE, Doshi HM 1992 Accumulation of p53 protein correlates with poorer prognosis in human lung cancer. Cancer Res 52: 4828-4831
39. Rasheed BKA, McLendon RE, Herndon JE, Friedman HS, Friedman AH, Bigner DD, Bigner SH 1994 Alterations of the TP53 in human gliomas. Cancer Res 54: 1324-1330
40. Sachs L 1992 Angewandte Statistik. Anwendung statistischer Methoden. Springer, Berlin
41. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang Z-F, Sheinfelf J, Fair WR, Herr HW, Reuter VE 1993 Nuclear overexpression of p53 in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Inst 85: 53-59
42. Sato T, Tanigami A, Yamakawa K, Akiyama F, Kasumi F, Sakamoto G, Nakamura Y 1990 Allelotype of breast cancer: cumulative allele losses promote tumour progression in primary breast cancer. Cancer Res 50: 7184-7189
43. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM 1990 The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1136
44. Schlegel U 1993 Molekulare Entstehungsmechanismen menschlicher Gliome. Nervenarzt 64: 485-493
45. Selter H, Montenarh M 1994 The emerging picture of p53. Int J Biochem 26: 145-154
46. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B 1992 Clonal expansion of p53 mutant cells is associated with brain tumor progression. Nature 355:846-847
47. Stephen CW, Lane DP 1992 Mutant conformation of p53. Precise epitope mapping using afilamentous phage epitope library. J Mol Biol 225: 577-583
48. Vogelstein B. Kinzler KW 1994 X-rays strike p53 again. Nature 370 174-175
49. Vojtesek R, Beirtek J, Midlgey CA, Lane DP 1992 An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Method 151: 237-244